Siwa Therapeutics
  • Home
  • Leadership
  • Science
  • Data
  • Media
    • News
    • Videos
  • Partners
  • Contact

Month: September 2019

Home / 2019 / September
26Sep 2019 by Andrew Premovich

In the News: Forbes

In The News
SIWA therapeutics was mentioned in an article at Forbes! See what they had to say about senolytic therapies and the future of aging.
Read More

Recent Posts

  • SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study
  • SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors
  • Listen to Ashley Jensen discuss SIWA’s antibody at AACR’s Virtual Conference!
  • Listen to Lewis Gruber speak at the 2021 Metabestiy conference
  • Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!

Archives

  • March 2022
  • February 2022
  • October 2021
  • April 2021
  • October 2020
  • September 2020
  • June 2020
  • May 2020
  • March 2020
  • February 2020
  • September 2019
  • March 2019
  • April 2018
  • June 2017
  • May 2017
  • October 2016

Categories

  • Events
  • In The News
  • News
  • Press Releases
  • Publications
  • Uncategorized

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on life-threatening cancers and related diseases with an unmet medical need (i.e., eligible for FDA Fast-tracking). We expect to file our first IND in late 2022.

Recent News

  • SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study
  • SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors
  • Listen to Ashley Jensen discuss SIWA’s antibody at AACR’s Virtual Conference!

JOIN OUR MAILING LIST

Navigation

  • Home
  • Leadership
  • Science
  • Data
  • Media
    • News
    • Videos
  • Partners
  • Contact